Daiichi Sankyo to close Japanese research and development subsidiary
Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.
Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.
Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.
Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.
The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).
Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines.
A global health care company Fresenius Kabi has announced the availability of Vasopressin injection, USP, in the US for treating adults with vasodilatory shock.
Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.
Private equity and growth capital firm EdgeCap Partners has acquired a majority stake in Bulgarian clinical research solutions organisation (CRO) Comac Medical.
Biopharmaceutical company Athenex and some of its subsidiaries voluntarily have filed Chapter 11 proceedings of the US Bankruptcy Code.
Swiss company SGS has purchased a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services as well as its subsidiaries (Nutrasource).